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Early-Phase Oncology Research Training (EFFORT) pro-
gram is a joint effort between Jiangsu Hengrui Medicine 
Co., Ltd, China and the United States–Chinese Anti-
Cancer Association (USCACA) to provide academic and 
financial support to junior clinical research staff includ-
ing physicians and nurses of early-phase oncology clini-
cal trial centers in China. The program will select 1–2 
qualified candidates per year and place them through 
rotation programs at 2–3 phase 1 cancer centers in the 
United States (US).
Current US cancer centers engaged in the EFFORT 
program include Wisconsin University Comprehensive 
Cancer Center, H. Lee Moffitt Cancer Center & Research 
Institute, and MD Anderson Cancer Center. The program 
also includes a rotation at Cancer Therapy Evaluation 
Program (CTEP) at National Cancer Institute. The dura-
tion of rotation is 4–8 weeks at each center. The exchange 
scholars will go through a structured clinical rotation 
with curriculum specifically designed for the individual 
needs and tailored for special features at each cancer 
center. The rotation at CTEP focuses on the clinical trial 
design, and the candidate will be part of the multi-disci-
plinary team to review, discuss, and evaluate study pro-
posals under the guidance of experienced CTEP medical 
staff. For more information about EFFORT, please see the 
article by Dr. Jingji Yang detailing the experiences from 
the pilot EFFORT program [1].
The program is overseen by a Governance Committee 
that consists of the following members.
  • Shu-Kui Qin, Nanjing Bayi Hospital, China; Immedi-
ate Past President of Chinese Society Clinical Oncol-
ogy (CSCO) and the President of CSCO Foundation
  • Lin Shen, Beijing Cancer Hospital, China
  • Weijing Sun, University of Pittsburg, USA
  • Yi-Long Wu, Gaungazhou General Hospital, China; 
President of CSCO
  • Li Xu, Vice President and Global Head of Oncology, 
Jiangsu Hengrui Medicine Co., Ltd; USCACA
  • Jie Wang, Beijing Cancer Hospital, China
  • Rui-Hua Xu, Sun Yat-sen University Cancer Center, 
China
  • Li Yan, Beijing Cancer Hospital, China; USCACA
  • Cai-Cun Zhou, Shanghai Pulmonary Hospital, Tongji 
University School of Medicine, China
The responsibilities of the Governance Committee 
include implementing the EFFORT program in China, 
e.g., distributing the program information through pro-
fessional organization (i.e., CSCO), hospitals, and cancer 
centers; identifying, reviewing, and qualifying candidates.
The EFFORT program is open to all junior clini-
cal research staffs in academic research centers that are 
accredited for phase 1 studies on oncology. In principle, 
the expenses of rotation program are shared between 
the candidates’ home institution in China and USCACA. 
USCACA is also responsible for designing the rotation 
program in collaboration with the home institution and 
the candidate.
The implementation of the EFFORT program is led by 
Drs. Roger Luo and Pascal (Jiang) Qian of USCACA. To 
apply, please contact USCACA at luofr@yahoo.com and 
pascal.qian@novartis.com. Please send your application 
with a brief introduction of your background and expe-
rience in clinical oncology trials, any particular aspects 
of the early clinical trials you are looking to strengthen, 
together with curriculum vitae (CV), the letter of support 
from the head of department and hospital providing the 
vision of your institution in early phase clinical oncology 
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trials, and the rationales why your participation in the 
program will benefit your home institution.
USCACA wants to take this opportunity to thank the 
following individuals in the US for their support to the 
Hengrui-USCACA Scholarship.
Dr. George Wilding and Ms. Dona Alberti, University 
of Wisconsin Carbone Cancer Center
Drs. Wei Sheng and Dan Sullivan, Moffitt Cancer 
Center
Drs. Helen Chen and Pamela Harris, CTEP at National 
Cancer Institute
Drs. David Hong, Funda Meric-Bernstam, Denise De 
La Cruz, and Sarina Anne Piha-Paul, MD Anderson Can-
cer Center
The program would be impossible without the gen-
erous grant from Jiangsu Hengrui Medicine Co., Ltd, 
China. The USCACA want to thank Mr. Piaoyang Sun, 
Drs. Li Xu, and Lianshan Zhang for their support of the 
program.
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